enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.98% | 35.63% | 21.54% | 19.61% | 20.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.11% | 50.74% | 63.48% | 97.71% | 82.94% |
| Operating Income | -35.11% | -50.74% | -63.48% | -97.71% | -82.94% |
| Income Before Tax | -38.91% | -59.62% | -77.43% | -112.65% | 23.01% |
| Income Tax Expenses | -196.32% | -204.03% | -162.07% | 100.00% | 2,557.14% |
| Earnings from Continuing Operations | -37.63% | -58.80% | -77.33% | -112.73% | 22.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.63% | -58.80% | -77.33% | -112.73% | 22.58% |
| EBIT | -35.11% | -50.74% | -63.48% | -97.71% | -82.94% |
| EBITDA | -34.96% | -50.62% | -63.44% | -97.92% | -83.14% |
| EPS Basic | -9.39% | -31.87% | -47.50% | -52.27% | 98.40% |
| Normalized Basic EPS | -10.11% | -32.11% | -47.11% | -53.78% | 95.02% |
| EPS Diluted | -9.39% | -31.87% | -47.50% | -52.27% | 98.40% |
| Normalized Diluted EPS | -10.11% | -32.11% | -47.11% | -53.78% | 95.02% |
| Average Basic Shares Outstanding | 30.67% | 25.64% | 23.31% | 35.20% | 83.71% |
| Average Diluted Shares Outstanding | 30.67% | 25.64% | 23.31% | 35.20% | 83.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |